Last reviewed · How we verify
QL1706
QL1706 is a small molecule targeting the PI3K/AKT pathway to inhibit cancer cell growth.
QL1706 is a small molecule targeting the PI3K/AKT pathway to inhibit cancer cell growth. Used for Metastatic non-small cell lung cancer, Metastatic breast cancer.
At a glance
| Generic name | QL1706 |
|---|---|
| Also known as | bevacizumab, albumin-binding paclitaxel, Iparomlimab and Tuvonralimab Injection, Iparomlimab and Tuvonralimab，PSB205, PSB205 |
| Sponsor | Fujian Cancer Hospital |
| Drug class | PI3K/AKT pathway inhibitor |
| Target | PI3K/AKT pathway |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
QL1706 works by binding to the PI3K/AKT pathway, which is involved in cell growth and survival. This binding inhibits the pathway, leading to reduced cancer cell growth and proliferation.
Approved indications
- Metastatic non-small cell lung cancer
- Metastatic breast cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- QLS5132 Combination Therapy in Advanced Solid Tumors (PHASE1, PHASE2)
- An Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLC (NA)
- A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer (PHASE2)
- SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases (PHASE2)
- QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer (PHASE2)
- Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer (PHASE2)
- PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC (PHASE2)
- Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QL1706 CI brief — competitive landscape report
- QL1706 updates RSS · CI watch RSS
- Fujian Cancer Hospital portfolio CI